Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

NanoViricides Soaring On Great News

|Includes: NanoViricides, Inc. (NNVC)

One of my "Explore Portfolio" speculation stocks, NanoViricides (Ticker and my charts at NNVC), is soaring on a recent batch of great news.

NNVC Chart

You can read a summary of the news here. Excerpts:

  • NanoViricides Signs a Non-Disclosure Agreement with the Lovelace Respiratory Research Institute for IND-enabling Efficacy Studies on FluCideĀ® and for Testing its Novel Drug Candidates against the Highly Lethal MERS Human Coronavirus
  • The Company has already shown that the injectable and oral FluCide drug candidates are substantially more effective than oseltamivir (TamifluĀ®) in controlling influenza A virus infections in a highly lethal animal model using two unrelated subtypes of influenza A, namely H1N1 and H3N2.
  • NanoViricides Receives Notification that Clinical Coordinators Have Been Appointed by The European Medicine Agency to Review the Company's Upcoming DengueCide Orphan Drug Designation Application
  • There is currently neither an effective drug treatment nor a vaccine for dengue virus infection.

Excerpts from my Newsletter about NanoViricides, Inc.

and

Disclosure: I am long NNVC.